Trial intelligence / Profile preview

Randomized open-label study of BMS-354825 vs high-dose imatinib in imatinib-resistant chronic phase Ph+ CML

2004-004450-96Phase 2Completed

Sponsor

Bristol Myers Squibb

Start

Dec 2004

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1